Literature DB >> 25443495

Tertiary lymphoid structures in cancer and beyond.

Marie-Caroline Dieu-Nosjean1, Jérémy Goc1, Nicolas A Giraldo1, Catherine Sautès-Fridman1, Wolf Herman Fridman2.   

Abstract

Tertiary lymphoid structures (TLS) are ectopic lymphoid formations found in inflamed, infected, or tumoral tissues. They exhibit all the characteristics of structures in the lymph nodes (LN) associated with the generation of an adaptive immune response, including a T cell zone with mature dendritic cells (DC), a germinal center with follicular dendritic cells (FDC) and proliferating B cells, and high endothelial venules (HEV). In this review, we discuss evidence for the roles of TLS in chronic infection, autoimmunity, and cancer, and address the question of whether TLS present beneficial or deleterious effects in these contexts. We examine the relationship between TLS in tumors and patient prognosis, and discuss the potential role of TLS in building and/or maintaining local immune responses and how this understanding may guide therapeutic interventions.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  cancer; immunotherapy; prognostic biomarker; tertiary lymphoid structure

Mesh:

Substances:

Year:  2014        PMID: 25443495     DOI: 10.1016/j.it.2014.09.006

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  177 in total

Review 1.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

2.  Plasma cells in primary melanoma. Prognostic significance and possible role of IgA.

Authors:  Francesca M Bosisio; James S Wilmott; Nathalie Volders; Marjorie Mercier; Jasper Wouters; Marguerite Stas; Willeke Am Blokx; Daniela Massi; John F Thompson; Richard A Scolyer; Nicolas van Baren; Joost J van den Oord
Journal:  Mod Pathol       Date:  2016-02-12       Impact factor: 7.842

Review 3.  Current concept for tertiary lymphoid structures in urothelial carcinoma of the bladder: a literature review and our experience.

Authors:  Milena Gulinac; Dorian Dikov; Simeon Lichev; Tsvetelina Velikova
Journal:  Am J Clin Exp Immunol       Date:  2020-12-15

4.  CIITA-driven MHC class II expressing tumor cells can efficiently prime naive CD4+ TH cells in vivo and vaccinate the host against parental MHC-II-negative tumor cells.

Authors:  Farah Bou Nasser Eddine; Greta Forlani; Letizia Lombardo; Alessandra Tedeschi; Giovanna Tosi; Roberto S Accolla
Journal:  Oncoimmunology       Date:  2016-11-28       Impact factor: 8.110

Review 5.  Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer.

Authors:  Si-Si Wang; Wei Liu; Dalam Ly; Hao Xu; Limei Qu; Li Zhang
Journal:  Cell Mol Immunol       Date:  2018-04-08       Impact factor: 11.530

6.  Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers.

Authors:  Xia Liu; Julia Y S Tsang; Thazin Hlaing; Jintao Hu; Yun-Bi Ni; Siu Ki Chan; Sai Yin Cheung; Gary M Tse
Journal:  Oncologist       Date:  2017-07-12

Review 7.  Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy.

Authors:  Anne M Macpherson; Simon C Barry; Carmela Ricciardelli; Martin K Oehler
Journal:  J Clin Med       Date:  2020-09-14       Impact factor: 4.241

8.  Identification and Characterization of Tertiary Lymphoid Structures in Murine Melanoma.

Authors:  Anthony B Rodriguez; J David Peske; Victor H Engelhard
Journal:  Methods Mol Biol       Date:  2018

Review 9.  Neoantigen-based cancer immunotherapy.

Authors:  Sara Bobisse; Periklis G Foukas; George Coukos; Alexandre Harari
Journal:  Ann Transl Med       Date:  2016-07

10.  Formation and phenotypic characterization of CD49a, CD49b and CD103 expressing CD8 T cell populations in human metastatic melanoma.

Authors:  Marit M Melssen; Walter Olson; Nolan A Wages; Brian J Capaldo; Ileana S Mauldin; Adela Mahmutovic; Ciara Hutchison; Cornelis J M Melief; Timothy N Bullock; Victor H Engelhard; Craig L Slingluff
Journal:  Oncoimmunology       Date:  2018-08-06       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.